About 38,800 people were newly diagnosed with HIV in the US in 2023, and an estimated 1.12 million Americans are living with HIV: roughly two-thirds of them virally suppressed CDC, 2023. Diagnoses cluster in the South. What drives most new infections now is the gaps along the care continuum, not any limit in the science.
Key figures
- People with HIV (US)
- ~1.12M
- about 13% are undiagnosed
- New diagnoses (2023)
- ~38,800
- CDC surveillance
- Virally suppressed
- majority
- of those in care, the continuum goal
- Undetectable
- U=U
- no sexual transmission
| Item | Value |
|---|---|
| People with HIV (US) | ~1.12M: about 13% are undiagnosed |
| New diagnoses (2023) | ~38,800: CDC surveillance |
| Virally suppressed | majority: of those in care, the continuum goal |
| Undetectable | U=U: no sexual transmission |
The headline numbers, at a glance
About 1.12 million people are living with HIV in the US right now, and around 38,800 were newly diagnosed in a single recent year. Of everyone living with the virus, roughly 723,000, close to two in three, have an undetectable viral load, meaning the virus is controlled and untransmittable. The geography is lopsided: the highest diagnosis rates sit in Washington DC and a band of Southern states.
Three numbers tell the story: people living with HIV, people newly diagnosed, and people virally suppressed. The first is the size of the epidemic. The second tells you whether it's growing. The third tells you whether we're winning, because a suppressed virus doesn't spread and doesn't progress.
How many people have HIV, US and global
An estimated 1.12 million people are living with HIV in the US. That figure includes people who know their status and a smaller group who don't yet. Undiagnosed people can't start treatment, and they unknowingly account for a large share of onward transmission. HIV attacks the immune system, and without treatment it moves through three stages: acute, a long chronic phase that can run a decade or more, and AIDS, defined by a CD4 count under 200 cells/mm³ or an opportunistic infection CDC.
There's no cure, but that means less than it used to. With modern treatment, a 20-year-old who starts before their CD4 count drops below 200 has a life expectancy approaching the general population's Lancet HIV. HIV today is a manageable, lifelong condition, and what matters most is whether people get diagnosed and treated in time.
Who is most affected, demographics and geography
HIV in the US is not evenly distributed, and the disparities are stark. The South carries the heaviest burden by far. In 2023 the highest diagnosis rates were in Washington DC at 33 per 100,000, followed by Georgia at 26, and Florida and Louisiana each at 23. These track with poverty, gaps in healthcare access, stigma that discourages testing, and uneven access to prevention tools like PrEP.
Geographic clustering also reflects who lives where and what barriers they face. A new diagnosis in a rural Southern county often means a longer drive to a clinic, fewer providers comfortable prescribing PrEP, and less anonymity, all of which delay testing and care. The virus doesn't care about ZIP codes, but the systems around it do.
New diagnoses: which way is the trend going
The roughly 38,800 new diagnoses in a recent year represent a long, slow decline from the epidemic's peak, but progress has been uneven and has stalled in some groups even as it improved in others. A diagnosis count isn't the same as new infections; it reflects both how many people acquired HIV and how many finally got tested. Testing rates shape the numbers as much as the virus does.
Acute HIV, the first few weeks after infection, is both easy to miss and highly contagious. Most people develop flu-like symptoms, fever, rash, sore throat, swollen lymph nodes, two to four weeks after infection, right when the viral load peaks above a million copies/mL and transmission risk is at its highest HHS. People often mistake this for the flu and never test, which fuels onward spread. If you've had a risk and then feel flu-ish, get an urgent test rather than waiting it out. Read more on what acute HIV infection looks like.
The care continuum: diagnosed → in care → virally suppressed
Public-health experts track HIV through the "care continuum," a series of steps where people can fall through the cracks: getting diagnosed, getting linked to care, staying in care, and reaching viral suppression. Every drop-off between those steps is a person whose health is at risk and who may unknowingly transmit the virus.
The single most useful US number here is suppression. About 723,000 of the 1.12 million people living with HIV, roughly two-thirds, are virally suppressed. That's the win column, because a suppressed virus protects both the individual and their partners. The remaining third are either undiagnosed, not in care, or not yet on stable treatment, and closing that gap is where most of the achievable progress lives. Understanding your own HIV cd4 count & viral load tells you where you stand on this continuum.
The science underneath suppression is solid. The CDC's Treatment as Prevention message, Undetectable equals Untransmittable, or U=U, means a person who takes their medicine and stays undetectable will not transmit HIV to sex partners CDC. Across the PARTNER studies, mixed-status couples logged tens of thousands of condomless sex acts with zero linked transmissions while the positive partner was suppressed PARTNER. Most people reach undetectable within about six months of starting treatment. If side effects are your worry, here's a guide to HIV treatment side effects.
How US numbers compare globally
The US epidemic is one slice of a much larger global picture. Worldwide, tens of millions of people live with HIV, with the heaviest burden in sub-Saharan Africa, orders of magnitude beyond the US count. The central challenge is the same in high-burden regions as it is here: the limiting factor isn't medication that works, it's getting people diagnosed, on treatment, and kept in care.
The prevention toolkit is the same everywhere, but access differs. Newer long-acting options are starting to change the math globally. Twice-yearly injectable lenacapavir produced zero infections among women in the PURPOSE 1 trial, the strongest HIV-prevention result recorded so far WHO. Tools like that matter most exactly where daily pills are hardest to sustain.
What the numbers mean for testing and prevention
Strip the statistics down and they point in one direction: get tested, and use the prevention tool that fits your life. The USPSTF gives HIV screening a Grade A recommendation: everyone ages 15 to 65 should be screened at least once, and those at higher risk repeated at least annually USPSTF. Symptoms can't confirm or rule out HIV; only a test can. You can get tested with a quick finger-stick or oral-swab rapid test that returns results in minutes, a lab blood test, or an at-home kit, and many health departments offer it free.
Timing matters. Each test type has a window period before it can reliably detect infection, so a negative is only conclusive after the window with no exposure during it. Check the when to test after exposure guide before assuming a result. The window types compare like this:
| Test type | Detects | Window after exposure |
|---|---|---|
| Nucleic-acid test (NAT) | Viral RNA | 10–33 days |
| Antigen/antibody (4th-gen) lab test | p24 antigen + antibodies | 18–45 days |
| Antibody / rapid test | Antibodies | 23–90 days |
On prevention, the numbers reward the right tool used the right way:
- PrEP, for people without HIV, reduces risk from sex by about 99% and from injection drug use by at least 74% when taken as prescribed CDC, daily pills (Truvada or Descovy) or the every-two-months cabotegravir shot.
- PEP is the emergency option: a 28-day course that must start within 72 hours of a possible exposure CDC. It cut seroconversion by about 81% in the original study, and only when started fast.
- Treatment as prevention (U=U) means a partner who's undetectable doesn't transmit, so prevention and treatment come together.
- Condoms and regular testing round out the CDC's core toolkit.
A common, costly mistake is waiting and testing after a recent high-risk exposure when you should be calling about PEP. PEP is a same-day ER or urgent-care conversation, not something to schedule next week. PrEP, by contrast, prevents infection going forward and needs a confirmed negative test first. If you're choosing where to get screened, you can compare testing providers.
When to see a clinician
Book a test if you've never been screened, that one-time check applies to nearly every adult. Go sooner if you've had a new partner, condomless sex, a partner whose status you don't know, or shared injection equipment; repeat at least yearly if any of that is ongoing. And if you develop fever, rash, sore throat, and swollen glands a couple of weeks after a possible exposure, treat it as urgent rather than as a passing flu.
If a possible exposure happened in the last three days, don't wait for symptoms or a test result: that's the PEP window, and every hour counts. After a confirmed diagnosis, start treatment as soon as possible, because early treatment is what makes a near-normal lifespan and U=U achievable CDC.
Keep exploring on EasySTD: STD incubation periods, how and where to get tested and HIV/AIDS testing.